Stay updated on LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial
Sign up to get notified when there's something new on the LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial page.

Latest updates to the LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial page
- Check2 days agoChange DetectedDifference2%
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference1%
- Check16 days agoChange DetectedDifference2%
- Check24 days agoChange DetectedThe page has removed detailed information about a Phase 1 clinical trial for LAVA-051, including key inclusion and exclusion criteria for participants, while adding a new revision number.SummaryDifference22%
- Check31 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has been changed from March 25, 2025, to January 27, 2025.SummaryDifference2%
- Check38 days agoChange DetectedThe page has removed references to Acute Graft Versus Host Disease and added information about Multiple Myeloma.SummaryDifference0.3%
Stay in the know with updates to LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial page.